Table of contents
In this issue
p333 | doi:10.1038/nrd1099
Editorial: A call to arms for drug discoverers
p335 | doi:10.1038/nrd1097
Research Highlights
Adme: Pressures in the pipeline
p337 | doi:10.1038/nrd1095
Inflammation: Promise for glycolysis inhibitor
p338 | doi:10.1038/nrd1094
Neurodegenerative diseases: Ferritin out iron's role
p338 | doi:10.1038/nrd1102
Therapeutic proteins: Glycoengineered to last longer
p339 | doi:10.1038/nrd1096
Biotechnology: Fingers in the genome pie
p340 | doi:10.1038/nrd1092
Diabetes: GPR40 no longer an orphan
p340 | doi:10.1038/nrd1093
Gpcrs: Rules of attraction
p341 | doi:10.1038/nrd1101
In brief
Kinase Inhibitors | Anticancer Drugs | Anti-obesity Drugs | Anticancer Drugs
p341 | doi:10.1038/nrd1103
Anticancer drugs: Breaking down resistance
p342 | doi:10.1038/nrd1104
News and Analysis
Patent watch
Method of treatment must be specific | GSK's Paxil given notice
p342 | doi:10.1038/nrd1105
From the analyst's couch
Statins – the heart of the matter
p343 | doi:10.1038/nrd1090
Fresh from the Pipeline
Enfuvirtide
p345 | doi:10.1038/nrd1091
Reviews
The dawning era of polymer therapeutics
Ruth Duncan
p347 | doi:10.1038/nrd1088
Drug discovery with engineered zinc-finger proteins
Andrew C. Jamieson, Jeffrey C. Miller & Carl O. Pabo
p361 | doi:10.1038/nrd1087
Article series: A guide to drug discovery
A guide to drug discovery: Hit and lead generation: beyond high-throughput screening
Konrad H. Bleicher, Hans-Joachim Böhm, Klaus Müller & Alexander I. Alanine
p369 | doi:10.1038/nrd1086
Pharmacological strategies for muscular dystrophy
Tejvir S. Khurana & Kay E. Davies
p379 | doi:10.1038/nrd1085
Such stuff as dreams are made on: mediator-directed therapy in sepsis
John C. Marshall
p391 | doi:10.1038/nrd1084
Perspective
Opinion
Is there a future for 'speculative' gene patents in Europe?
Devanand J. Crease & George W. Schlich
p407 | doi:10.1038/nrd1089
Natureview: Reviews and comment from the nature publishing group
p411 | doi:10.1038/nrd10908
Careers and Recruitment
Does size really matter?
Simon Frantz & Paul Smaglik
p413 | doi:10.1038/nrd1100
